Recent Updates
Recently added Catalysts
OM Negative Sentiment Score: 25/100

Outset Medical, Inc. (OM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: Outset Medical, Inc. is currently under investigation by Bronstein, Gewirtz & Grossman, LLC on behalf of investors due to significant financial underperformance. The company reported its Q2 2024 results on August 7, 2024, which missed consensus estimates, prompting a drastic reduction in its full year outlook. Consequently, shares dropped by over 68% the following day. Investors are encouraged to report any relevant information regarding their investments in Outset securities.

Market Sentiment Analysis

CONCERNS & RISKS

  • Outset Medical missed consensus estimates for its Q2 2024 financial results.
  • The company lowered its full year 2024 outlook significantly.
  • Shares of Outset fell by 68.53% following the negative news.

Full Press Release Details

NEW YORK, Aug. 11, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Outset Medical, Inc. (“Outset” or “the Company”) (NASDAQ: OM). Investors who purchased Outset securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/OM.
Investigation Details
On August 7, 2024, Outset released its second quarter 2024 financial results. The Company missed consensus estimates by a considerable margin and lowered its full year 2024 outlook. According to the Company, the “changes [it] needs to make are entirely in [its] control” and will involve “shifts and adjustments” to its sales team and processes. Based on this news, shares of Outset fell by 68.53% on August 8, 2024.
If you are aware of any facts relating to this investigation or purchased Outset securities, you can assist this investigation by visiting the firm’s site: bgandg.com/OM. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the investigation about Outset Medical?

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors in Outset Medical, following their missed financial estimates.

Why did Outset's shares fall significantly?

Outset shares dropped by 68.53% after the company lowered its 2024 outlook on August 7, 2024.

Is there a cost to participate in the investigation?

There is no cost to you; the firm works on a contingency fee basis.

How can I assist in the Outset investigation?

You can help by visiting bgandg.com/OM or contacting the firm directly.

What is the track record of Bronstein, Gewirtz & Grossman?

The firm has a strong reputation and has recovered hundreds of millions for investors.

Last updated: Aug 11, 2024